Swedish Orphan Biovitrum AB (publ) (STO:SOBI)
Sweden flag Sweden · Delayed Price · Currency is SEK
298.80
+2.20 (0.74%)
May 6, 2025, 5:29 PM CET

Swedish Orphan Biovitrum AB Company Description

Swedish Orphan Biovitrum AB (publ), a biopharma company, provides medicines in the areas of haematology, immunology, and specialty care in Europe, North America, the Middle East, Asia, and Australia.

The company operates through three segments: Haematology, Immunology, and Specialty Care. It offers Alprolix for haemophilia B; ALTUVOCT for the treatment and prophylaxis of bleeding in patients with haemophilia A; Aspaveli/Empaveli for treating adult patients with paroxysmal nocturnal haemoglobinuria; Doptelet for the treatment of immune thrombocytopenia and thrombocytopenia; Elocta/Eloctate for the treatment and prophylaxis of bleeding in patients with haemophilia A; Gamifant for treating hemophagocytic lymphohistiocytosis; Kineret for the treatment of cryopyrin-associated periodic syndrome, rheumatoid arthritis, familial Mediterranean fever, deficiency of interleukin-1 receptor antagonist, and systemic juvenile idiopathic arthritis; Orfadin for hereditary tyrosinemia type 1 and alkaptonuria; Synagis for the prevention of serious lower respiratory tract infection caused by respiratory syncytial virus in infants and young children; VONJO, a kinase inhibitor indicated for the treatment of post-polycythemia vera or post-essential thrombocythemia myelofibrosis; and Zynlonta for treating adult patients with relapsed or refractory diffuse large and high grade B-cell lymphoma.

The company also provides other medicines, such as Akynzeo, Aloxi, Jyseleca, Kepivance, Tegsedi, and Waylivra, as well as develops drug substances for ReFacto AF/Xyntha for Pfizer.

The company has collaboration agreements with Sanofi, Apellis Pharmaceuticals, Inc., ADC Therapeutics SA, and Cartesian Therapeutics, Inc. Swedish Orphan Biovitrum AB (publ) was incorporated in 1939 and is headquartered in Stockholm, Sweden.

Swedish Orphan Biovitrum AB (publ)
Swedish Orphan Biovitrum AB logo
Country Sweden
Founded 1939
Industry Drug Manufacturers - Specialty & Generic
Sector Healthcare
Employees 1,806
CEO Guido Oelkers

Contact Details

Address:
Norra Stationsgatan 93A
Stockholm
Sweden
Phone 46 86 97 20 00
Website sobi.com

Stock Details

Ticker Symbol SOBI
Exchange Nasdaq Stockholm
Share Class Class A Shares
Fiscal Year January - December
Reporting Currency SEK
ISIN Number SE0000872095
SIC Code 2836

Key Executives

Name Position
Dr. Guido Oelkers Ph.D. Chief Executive Officer and President
Henrik Stenqvist Chief Financial Officer
Torbjörn Hallberg General Counsel and Head of Legal Affairs
Daniel Rankin Head of Strategy and Corporate Development
Lena Bjurner Head of Human Resources
Norbert Oppitz Head of International
Sofiane Fahmy Head of Europe
Duane H. Barnes Head of North America
Mahmood Ladha Head of Strategic Transformation Operations
Christine Wesstrom Head of Technical Operations